Lancet Haematol: CD20 monoantigen obinutuzumab combined with DHAP to treat the efficacy of suite cell lymphoma.

Obinutuzumab single-drug treatment of membrane cell lymphoma showed good results.
LyMa-101 is a forward-looking, open-label, one-arm Phase 2 trial designed to investigate the activity of obinutuzumab combined with DHAP (dexamysone, high-dose agarose and cisplatin).
recruited newly diagnosed patients (18-66 years old) with autogenic stem cell transplants from 28 hospitals in France for four courses of obinutuzumab and DHAP.
end of the treatment is the negative minimum residual lesions of the bone marrow after treatment.
November 29, 2016 - May 2, 2018, a total of 86 patients were recruited, 81 of whom completed induction therapy, 73 had an induced stem cell transplant, and 69 patients began maintenance therapy.
(75%) of the 73 patients in the efficacy set reached bone marrow micro-residual lesions negative at the end of induced chemotherapy.
According to the programme, 18 patients (25%) were positive for micro-residual lesions: 12 were positive for micro-residual lesions of bone marrow, 2 were positive for course progression during induction chemotherapy, and 4 were not evaluated for micro-residual lesions.
the most common adverse reactions to emergency treatment at levels 3-4 were anemia (level 3, 36/85, 31 per cent; level 4, 4 per cent) and a decrease in neutral granulocytes (level 3, 15 per cent; level 4, 38 per cent).
58 severe adverse reactions occurred during the induction phase.
treatment-related deaths.
, obinutuzumab combined with DHAP is well-to-resistant for transplantable sleeve lymphoma and has good activity in inducing micro-residual lesions negative.
obinutuzumab combined with DHAP as an induced chemotherapy has potential activity, and a negative bone marrow micro-residual lesions may predict long-term disease control.
.